chrisvoncsefalvay/vaers-outcomes huggingface dataset:
About 10:30 PM, started getting a slight headache with accompanying symptoms of a urinary tract infection. The urgent need to go to the bathroom and the sensation of pins and needles at the end of urinating. Trying to drink a lot of fluids but it?s not helping much. Not seeing any blood on the tissue paper at the end as with typical UTIs
Widespread itchy, burning rash over much of trunk, arms, and thighs. Rash usually began to appear in the late afternoon or evening and became more widespread overnight, but then completely disappeared the next morning. This repeated for four days.  Medication - benadryl (25 mg) every 4-5 hr.; loratadine (10 mg) once daily last two days
I received my third dose on 12/1/2021. On 01/09/2022 I woke up and had hip pain down from thigh to knee. I was unable to walk or sleep. I went to a chiropractor 2x a week for a month. I did acupuncture 2x a week for 4 weeks. Very little relief. I went to PCP and was prescribed prednisone and that did nothing. Now I started physical therapy twice a week for four weeks so far.
30 minutes post vaccination: It was an extremely dry mouth and tongue and throat was weird and felt like it was closing up. Heart rate was way up too. But it was all over within 15 minutes or so.
Seen at school board by health dept for Hep B shot states approx 45 mins after shot had to pull over in car and vomit. States approx 1 1/2 hours after shot students noted red blotches on neck, felt a little light headed but other wise no S/S. Ok today, blotches still some what apparent on neck.
Patient received Moderna vaccine Lot #045A21A instead of a Pfizer dose given age at that time (16), on 03/19/2021. Vaccine was administered in March, we were made aware by database months after vaccine was administered. For item 21 "none of the above" is selected because we were notified of adverse event after vaccine administration and were unable to document outcomes in a timely manner. Consequently, patient also received second dose on 0416/2021.
Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Additional Details: Patient reported significant swelling and a 4 inch raised hive at injection site. Patient took Benadryl and it went down and resolved after a few days. Reaction started on day 8 after injection.
Rash for 2 days on face, neck, chest, abd., and back. Fever 101.0 F T-max 103.4F.
12 year old was given Intradermal flu vaccine on XX/XX/11. Lot number of UT4163AA, Sanofi Past, given in left deltoid area. Fifty cent piece swollen, red, warm area at injection site 15 hrs after injection.. this occurred at local health dept. This was the 3rd person that we had given this presentation to and did not confirm the age limit. This young man is very afraid of injections and was thrilled with this possibility. We are both aware of the recom age limits now.
Presented on 5/15 with chest pain and diffuse ST segment elevation consistent with perimyocarditis. He received his second COVID vaccine (5/11) 4 days ago- reports 3 days ago feeling sinus inflammation, throat felt swollen, and laid in bed all day, 2 days ago- he reports just having sinus inflammation sensation, 5/10- he reports feeling like every muscle including his neck hurt. No headache, vision changes, weakness, tingling. No cardiac history, leg swelling, rash, rhinorrhea, or recent illness.
Arrived at our installation on 10/16/06 and reported c/o chest pain within 2 hours of arrival. He was taken to theER and evaluated. Apparently had received his smallpox vaccination on 05Oct06, approximately 8 days later he developed fever, aching and tender lymph nodes. 2 days following this he noted some pain in his left chest between the axilla and middle chest, symptoms did not increase in inhalation/exhalation. He has had past medical history of severe anxiety episodes with chest pain per patient. Soldier reported pain level at a 2 to 3 out of ten during ER visit. Lab testing done. Diagnosed as Chest pain, possibly associated with a smallpox vaccination but without any signs of any specific pericarditis or myocarditis. Patient was seen on follow up on 10/18/06 and soldier reported that he was feeling well. Released without limitations.  10/30/06 Received hospital ER medical records which reveal patient had received vax 10/5 & developed fever, achiness & axillary lymph node tenderness 8 days later.  Two days prior to ER, had left chest pain between axilla & mid chest. PMH: severe anxiety episodes with chest pain. Dx: chest pain, possible associated with smallpox vax but w/o any signs of pericarditis or myocarditis. Was to rest in ER over night & f/u with Troop medical clinic in AM.  No treatment rendered./ss
it's been more than 42 days after the first dose without receiving the second dose; had covid; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (had covid) and PRODUCT DOSE OMISSION ISSUE (it's been more than 42 days after the first dose without receiving the second dose) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, the patient experienced COVID-19 (had covid). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (it's been more than 42 days after the first dose without receiving the second dose). At the time of the report, COVID-19 (had covid) and PRODUCT DOSE OMISSION ISSUE (it's been more than 42 days after the first dose without receiving the second dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided by reporter.  Treatment information was not provided by reporter.  The patient needed an antibodies infusion for Covid, and reporter wanted to know if it is necessary for patient to have a second dose of the Moderna Covid19 Vaccine.
got the shot on 1/17/21, really didn't have any adverse reactions until 1/27 about 10 pm, as I was getting ready for bed.  Then I noticed a  redness on right arm at site of shot, a circular redness.  This has stayed the same since the 27th.  Once in a while it has been a little itchy and warm to the touch.  Also a little touch produces a little tenderness.  No treatment yet.  Will call primary care physician on 2/01/21 if still red.
pt recv vax 7 days prior to onset of sx;1wk prior to flu shot had viral URI;pt did not require tx w/IVIG;pt recovered & was discharged home;
vaccine exposed at below 30-32 F for one hour due to opening and closing of refrigerator door/no AE; Initial information received on 19-Jun-2020 regarding an unsolicited valid non-serious case received from a physician.  This case is linked to cases 2020SA161181, 2020SA161182, 2020SA161183, 2020SA161064 and 2020SA161203 (same reporter).  This case involves a 4 month old female patient who was vaccinated with DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL] which was exposed at below 30-32 Fahrenheit for one hour due to opening and closing of refrigerator door (product storage error).  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included PNEUMOCOCCAL VACCINE CONJ 7V (CRM197) (PREVNAR) for Immunisation; and ROTAVIRUS VACCINE (ROTAVIRUS VACCINE) for Immunisation.  On 15-Jun-2020, the patient received second 0.5 ml dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE (lot UJ015AAA and expiry date 26-Oct-2020) via an intramuscular route in the left thigh for prophylactic vaccination.  It was a case of an actual medication error due to product storage error temperature too low.  At the time of reporting, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
stroke; tested positive for Covid; Covid-19; lost bowel function; got sick  4 hours later; This spontaneous case was reported by a consumer and describes the occurrence of CEREBROVASCULAR ACCIDENT (stroke) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 in December 2020. Concurrent medical conditions included Type 2 diabetes mellitus. Concomitant products included INSULIN DETEMIR (LEVEMIR) and INSULIN for Type 2 diabetes mellitus.    On 03-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-May-2021, the patient experienced FUNCTIONAL GASTROINTESTINAL DISORDER (lost bowel function) and ILLNESS (got sick  4 hours later). On an unknown date, the patient experienced CEREBROVASCULAR ACCIDENT (stroke) (seriousness criterion medically significant), SARS-COV-2 TEST POSITIVE (tested positive for Covid) and COVID-19 (Covid-19). At the time of the report, CEREBROVASCULAR ACCIDENT (stroke), FUNCTIONAL GASTROINTESTINAL DISORDER (lost bowel function), ILLNESS (got sick  4 hours later), SARS-COV-2 TEST POSITIVE (tested positive for Covid) and COVID-19 (Covid-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: negative (Negative) Negative and positive (Positive) Positive.         The patient had stroke 2 days later to the second dose vaccination and was rushed/admitted to the ER for a while.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Based on the mechanism of action of mRNA-1273, the event (Covid-19) is assessed as unlikely related to mRNA-1273.   This case was linked to MOD-2021-117175 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Based on the mechanism of action of mRNA-1273, the event (Covid-19) is assessed as unlikely related to mRNA-1273.
A few hours after receiving my fourth dose of my Pfizer COVID-19 vaccine, I had chills and an elevated temperature of around 101. I had the chills off and on for several hours and the fever lasted for around 2 days, until the morning of 05/26/2022. I was also having a bit of an upset stomach, but no vomiting. I was feeling achy and tired and just not feeling well at all for those 2 days. I also contracted COVID-19 on 08/19/2022. I was prescribed PAXLOVID. I experienced sore throat, coughing, severe headache, a fever that reached 101.8, and chills. Those symptoms lasted for around 3 days. Along with the PAXLOVID, my doctor advised that I take ROBITUSSIN DM and TYLENOL for my symptoms.
Breathing patterns changed within 24 hours. Deep breathing became difficult. Within 1-2 days later, the patient was standing and experienced inability to catch her breath. She was fighting to breathe and felt pain behind her left ear, extending down her neck. She felt dizzy and used a home blood pressure monitor, which registered 171/133. She instantly lay down to lower blood pressure and felt pinching pain down her left arm. 2 fingers in her left hand went numb and tingly. She called the nurse line and after sharing her age (only 27), the nurse decided to tell the patient to have someone drive her in, instead of advising to call 911. Doctors and intake nurses at first started to consider a stroke, but instantly rejected that as soon as they heard about the patient's age and did not take into consideration that the vaccination and all of the unnecessary antibiotics & antifungals could have stressed the body too much to handle a vaccine for pneumonia. After this incident, the patient continued to experience blood pressure issues - even developing DVT- for 2-3 years after this event. Since the vaccination, patient has had difficulty getting the deeper breaths that were possible prior to the vaccine. Patient went to a physical therapist for an unrelated issues, but the PT discovered that the muscles around the diaphragm were not working the way they should.
Skin discoloration. Pain in arm. Initial information was received on 08 January 2009 from a consumer in the United States. A cluster of one patient out of two vaccines received an intramuscular injection of Fluzone SV 2008-2009 (lot number not reported) on an unspecified date. A few days later the male patient's shoulder to elbow became red, "as if there were bleeding in the tissue". The area then turned blue, then black and took two to three weeks to clear up. The patient had an aching pain when his arm was abducted. The patient did not provide further details. 18 February 2009: A new case was created to add that the reported for this case is the same as for case 2008-03739. The sentence below was amended and case number 2008-03739 was added in addition to case 2009-00060. List of Documents held by Sender: None. The reporter of this case is same as for case numbers 2009-00060 and 2008-03739.
Pt was exposed to COVID 3 days prior to admission and received outpatient monoclonal antibody treatment.  He presented to the hospital with fatigue, decreased appetite, and confusion.
After patients second covid vaccine, patient states feeling confusion, tight throat, itchiness, weakness. Patient went to the ED for monitoring. VSS stable and discharged. no pharmacologic or laboratory interventions taken.
This case was reported by a consumer and described the occurrence of headache in a 42-year-old female subject who was inadvertently vaccinated with diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (Infanrix, GlaxoSmithKline). The reporter is the subject. A physician or other health care professional has not verified this report. The subject's medical history included allergic bronchopulmonary aspergillosis, allergies, elevated cholesterol, Hashimoto's disease and menopausal. Concurrent medications included Montelukast sodium (Singular), Thyroxine sodium (Levothyroxin), Atorvastatin calcium (Lipitor), Fluticasone propionate (Flonase), Calcitriol (Calcitrol), Calcium carbonate (OsCal 500), Estrogen (Estrogen patch), Fluticasone propionate (Flovent) and Prednisone.  On 06 November 2006 at 10:00 a.m., the subject inadvertently received 1st dose of Infanrix in the left arm. Infanrix is not recommended for immunizing individuals 7 years of age or older. On 06 November 2006, less than one day after vaccination with Infanrix, the subject experienced headache, chills, and injection site tenderness. On 07 November 2006, the subject experienced epistaxis. The subject was seen at physician's office. The chills resolved on 07 November 2006. At the time of initial reporting, 08 November 2006, the headache and injection site tenderness had improved and the epistaxis was ongoing.
pt recvd vax & approx 15-20 mins p/shot collapsed started convulsing; EMS took to hosp unresponsive when arrived;
Red, raised, circular rash behind each knee appearing within 14 days of immunization; resolved slowly over 2 weeks.
Patient tested positive for COVID-19 after 1st dose; Received her 1st dose on 05 Feb 2021; This spontaneous case was reported by an other health professional and describes the occurrence of SARS-COV-2 TEST POSITIVE (Patient tested positive for COVID-19 after 1st dose) and PRODUCT DOSE OMISSION ISSUE (Received her 1st dose on 05 Feb 2021) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SARS-COV-2 TEST POSITIVE (Patient tested positive for COVID-19 after 1st dose) and PRODUCT DOSE OMISSION ISSUE (Received her 1st dose on 05 Feb 2021). At the time of the report, SARS-COV-2 TEST POSITIVE (Patient tested positive for COVID-19 after 1st dose) and PRODUCT DOSE OMISSION ISSUE (Received her 1st dose on 05 Feb 2021) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 06-Jul-2021: Follow up received contain No new information.
she had a little bleed in the blood vessel of her left eye; This is a spontaneous report from a contactable other healthcare professional (patient). A female patient of unspecified age received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot/batch number and expiration date not provided), via an unspecified route of administration on 21Dec2020 at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient asking if bleeding of the eye was an adverse reaction to bnt162b2. Patient received the Covid vaccine on 21Dec2020 and on the 27Dec2020, she had a little bleed in the blood vessel of her left eye. She was supposed to get the second vaccine today (11Jan2021) at 12:30. The outcome of the event was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: A possible contributory effect of suspect BNT162B2 on reported event cannot be excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Patient complained of an allergie reaction. Onsite EMS was called vitals BP 174/90 HR 70 99% O2. She refused futher evaluation and released to go home.
Client c/o pain and weakness in right arm and hand.  Hand stiff and swollen.  Unable to lift a glass of milk.  C/o tingling and burning in elbow and shoulder.  Has had fever on and off.  Arm is constantly throbbing.  Pain wakes her up at night.  Instructed to be seen by primary care physician on 4/16/2012.
Pt recv vax on 8/11/98; on the same day pt exp flu-like achiness; pain in muscles of neck on side of injection, chills, crawling skin feeling on scalp & randomly throughout body for 2.5 dys.
This case was reported in a literature article and described the occurrence of uveitis in a 47-year-old female subject who was vaccinated with hepatitis B vaccine recombinant (Hepatitis B vaccine, manufacturer unspecified). On an unspecified date the subject received unspecified dose of Hepatitis B vaccine (unknown). At an unspecified time after vaccination with Hepatitis B vaccine, the subject experienced uveitis and retinopathy. This case was assessed as medically serious by GSK. This is one of the 32 reported cases (B0662264A till B0662297A) of uveitis which occurred after hepatitis b vaccine between 1982 and 2009. It appeared that all the subject's recovered, although the treatment for uveitis was not reported. The uveitis occurred in average of 3 days after vaccination in patients without other risk factors or disease that could cause uveitis. This could be consistent with immune complex deposition or nonspecific activation from vaccine adjuvants. Although there was a debate that uveitis occurs because of hepatitis B infection there was evidence that immune complex deposition diseases such as glomerulonephritis and cryoglobulinemia occurred during chronic hepatitis B infection. Furthermore it was possible the surface antigen of the vaccine and the hepatitis B antibodies of the immune response after vaccination formed immune complexes, which initiated the ocular response of uveitis.
Patient with hx of dementia had a televisit with PCP 3 days  on 9/17 with upper respiratory symptoms. Patient was swabbed for COVID and test resulted positive. Pt more confused than normal per wife; O2 sats on RA in ED 96% although desats to 88% with coughing. Patient admitted and started tx with dexamethasone (on going) and remdesivir x 2 days.
Small rash on injection site; Enlarged lymph sub clavicular lymph node left side; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM9810) via an unspecified route of administration in the left arm on 30Mar2021 at 14:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included allergies. Concomitant medications included probiotics (MANUFACTURER UNKNOWN) and omeprazole (JUICE PLUS OMEGA) for unknown indication from unknown date received within 2 weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration in the left arm on 09Mar2021 at 15:30 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient had known allergies to several medications, food, or other products. On 01Apr2021 at 13:00, the patient experienced small rash on injection site and enlarged lymph sub clavicular lymph node left side. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events vaccination site rash and sub clavicular lymphadenopathy was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Initial misuse report received from a healthcare professional on 13 March 2014. A patient under 3 years of age had received 0.5 ml dose of FLUZONE on an unspecified date. It was reported that the patient was given 0.5 ml of the vaccine. No adverse event ws reported. List of documents held by sender: none
So 10 days of breakthrough bleeding. Had a heavy period. Super bad for 10 days. Happen again a few months later in Aug 26,2021. Called my doctor and told them and they said it is common for that to happen. Just call when things got really bad.
temp 101-102F(r) on 7AUG; Fussy x 20 hrs, refused feedings; Consolable, no local rxn; 8AUG temp 101F, more alert, taking feedings;
Sharp pain in left side of neck, toward back.  Same side as injection (left side).  Discomfort level akin to "pulling a neck muscle."  Began about 20 minutes after injection; lasted for about two hours.  Lying down, resting, and applying heating pad to sore area eventually eliminated adverse reaction.  Event began at about 6:45 p.m.; discomfort ceased about 8:00 p.m.